Erythropoiesis Stimulating Agents and Tumor Progression (R01) | Apply Online

Opportunity Summary:

The Erythropoiesis Stimulating Agents and Tumor Progression (R01) opportunity (Funding Opportunity Number PA-09-023) is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement that supports research aimed at clarifying how erythropoietin (EPO) and related erythropoiesis-stimulating agents (ESAs) may influence tumor biology. ESAs have a long clinical history in treating anemia, especially anemia associated with renal failure, and they have also been used to manage anemia caused by cancer chemotherapy. The scientific and clinical concern driving this program is that multiple clinical trials in cancer populations raised red flags suggesting ESA administration might be linked to faster tumor progression and higher mortality in some settings. Because these findings carry major implications for patient safety and treatment decisions, the FOA emphasizes the need for rigorous mechanistic and translational research to understand whether, when, and how ESAs affect tumor cell growth, survival, and programmed cell death (apoptosis), as well as broader processes involved in tumor progression.

This announcement uses the NIH R01 mechanism, meaning it is intended for substantial, hypothesis-driven research projects with well-developed aims, strong preliminary rationale, and a clear plan for generating meaningful, publishable advances in cancer biology. The R01 format is typically suited to multi-year projects that can support a cohesive research program rather than a small pilot. The FOA also notes it runs in parallel with a companion announcement of identical scientific scope that uses the R21 exploratory/developmental mechanism (PA-09-024). In practical terms, that parallel structure signals NIH interest in both mature projects (R01) and earlier-stage, higher-risk concept testing (R21), all under the same broad goal of understanding ESA effects on tumors.

The central research theme is the biology of ESAs in the context of cancer, with particular attention to tumor cell proliferation and apoptosis, and how these cellular effects might translate into measurable tumor progression outcomes. The FOA is framed around resolving the gap between ESA benefits for anemia management and the troubling clinical signals that ESAs could worsen cancer outcomes in certain circumstances. Applications are therefore expected to probe mechanisms and contexts: for example, whether tumor cells express relevant receptors or signaling components, how EPO/ESA exposure influences intracellular pathways tied to growth and survival, and how those molecular and cellular changes could affect disease behavior. While the brief summary text does not list specific required models or endpoints, the intent is clearly to promote high-quality studies that can explain observed clinical outcomes and inform safer therapeutic use.

Funding under PA-09-023 is described as contingent on the availability of appropriations and on receiving a sufficient number of scientifically meritorious applications, which is standard NIH language indicating there is no guaranteed number of awards. The opportunity is categorized as a discretionary grant within health-focused activities, and it is associated with CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.396 (Cancer Biology Research). There is no cost-sharing or matching requirement, so applicants are not expected to provide non-federal matching funds as a condition of award.

Eligibility is broad and includes many organization types that commonly participate in NIH research funding. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) entities), small businesses, and for-profit organizations other than small businesses, as well as various government entities (state, county, city/township, special district, and independent school districts). The eligibility language also extends to additional categories such as eligible federal agencies, faith-based or community-based organizations, Hispanic-serving institutions, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This breadth reflects NIH’s interest in attracting strong proposals regardless of sector, provided the applicant can demonstrate the scientific capability, environment, and compliance infrastructure needed for an NIH-funded R01 project.

Key dates show the FOA was posted and created on November 6, 2008, with an original and current closing date of January 7, 2012, and an archive date of February 7, 2012. That means the announcement is no longer active for new submissions under those dates, but it remains important as a reference point for the kinds of questions NCI wanted answered about ESAs and tumor progression. For applicants or researchers trying to locate the full historical announcement details, the document points to the NIH Grants Guide link (http://grants.nih.gov/grants/guide/pa-files/PA-09-023.html). For technical problems accessing the announcement, the contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Erythropoiesis Stimulating Agents and Tumor Progression (R21)

Previous opportunity: Environmental Education Grants Solicitation Notice for 2009

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 023

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 023) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 023", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.